Ashwin Gopinath

Ashwin Gopinath is the co-founder of Biostate AI, a deep-tech company using artificial intelligence to revolutionize RNA sequencing and multi-omics. Ashwin is a highly distinguished researcher who holds a PhD from the University of California, Riverside, and served as an Assistant Professor at MIT and a research scientist at Caltech. His work sits at the intersection of nanotechnology and biological engineering, focusing on building high-throughput diagnostic tools. With the launch of Biostate AI, he is bringing academic-grade breakthroughs to the commercial market to enable faster and cheaper drug discovery. In 2025, he led the company to a successful Series A round backed by Accel, establishing Biostate as a leader in the Palo Alto biotech ecosystem.

Biostate AI is a biotechnology company that leverages artificial intelligence to drastically reduce the cost and time of RNA sequencing. By combining nanotechnology with machine learning, the platform allows researchers to perform multi-omics analysis with unprecedented precision. This technology is critical for the development of personalized medicine and the acceleration of clinical trials. Based in Palo Alto and backed by a 2025 Series A round from Accel, Biostate is positioning itself as the core data engine for the next generation of biotech breakthroughs.